Navigating recurrent Clostridioides difficile infection without Bezlotoxumab: potential challenges ahead

2025/01/01 by Radhika Arya, Alex N Zimmet, Marisa Holubar +1 · 1 voice
Medicine · Immunology and Microbiology · #Clostridium difficile and Clostridium perfringens research #Antibiotic Use and Resistance #Nosocomial Infections in ICU

paper · pdf · doi:10.1017/ash.2025.10144

openalex publication_date 2025/01/01 · openalex created_date 2025/12/10 · openalex updated_date 2026/06/26

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Discussions

• @radhikaarya.bsky.social: The withdrawal of bezlotoxumab leaves a gap in preventing recurrent C diff infection. This commentary reviews current strategies, including PO vancomycin ppx and fecal microb [bsky, 3 points, 0 comments]

Related

• Clinically important antimicrobial-resistant bacteria present in publicly accessible locations of a tertiary-care hospital
• Retrospective, single-center assessment of a pharmacist-led anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy bundle to enhance antimicrobial stewardship
• Improved guideline adherence may not overcome evidence gaps in severe trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia infection: a case-based perspective
• Guidance for infectious disease care in the face of human conflict: a case-based narrative review
• Integrating an industrial hygienist into the infection prevention and control program